ABOUT US
20/20 Onsite is a specialty vendor for sponsors and CROs conducting clinical trials with ocular endpoints, providing end-to-end ophthalmic trial consultation, clinical field execution, and ongoing support. Through a single-call accountability model, 20/20 Onsite helps sponsors de-risk ocular endpoint complexity and increase the likelihood of on-time, on-budget, protocol-adherent trial success.
Its proprietary point-of-need service delivery model reaches participants where they live, work, or congregate, reducing patient burden, improving retention, and supporting diverse enrollment strategies. Backed by proven expertise, nationwide experience at scale, and validated regulatory rigor, 20/20 Onsite has supported more than 45 clinical trials, served over 100,000 patients, and consistently delivered Net Promoter Scores above 95.
FEATURED ARTICLES
-
![GettyImages-820772090 eyes]( "Clinical Trial Data Quality In Neurology Studies")
Discover how standardized ocular biomarkers and point-of-need delivery safeguard data integrity in complex neurology trials while keeping patients engaged.
-
![Rare diseases, medical-GettyImages-2199746424]( "Clinical Trial Recruitment Strategies For Rare Disease Studies")
Discover how decentralized execution can rescue your recruitment strategy and safeguard your study's endpoints.
-
![cro-clinical-trials-GettyImages-1288871608]( "What Clinical Trial Management Solutions Don't Cover: The Ocular Endpoint Execution Gap")
Discover how specialized endpoint execution closes critical gaps in ophthalmic trials, improving assessment consistency, protocol adherence, data quality, and participant retention.
-
![20 20 onsite]( "Clinical Research Logistics: How Point-Of-Need Execution Protects Ocular Endpoints")
Reduce operational risk in ophthalmic trials with point-of-need execution. Discover how mobile clinics, specialized teams, and single-call accountability protect endpoint quality and study timelines.
-
![GettyImages-2223908587-doctor-patient]( "Ophthalmology Patient Engagement And Retention: Point-Of-Need Execution")
Dropout in retinal trials is often a logistical failure. Reducing travel burden and bringing specialized care to the patient can slash attrition rates and secure critical trial timelines.
-
![Close up on eyes GettyImages-1207244495]( "What Re-Acquisition In Retinal Imaging Is Really Costing Your Program")
High screen failure rates and patient dropout often stem from preventable imaging errors. Learn how proactive quality control and patient-centric logistics secure critical retinal trial data.
-
![Digital Eye-GettyImages-2184122570]( "When Your Protocol Includes Ocular Endpoints")
Standardizing ocular endpoint execution reduces participant dropout and eliminates data variability. Specialized oversight secures clinical timelines and ensures high-quality, submission-ready data.
-
![GettyImages-1153115028-ocular-eye-exam]( "Ocular Hypertension In Clinical Trials: Protecting IOP Endpoints From Execution Risk")
Fluctuations in eye pressure measurements can jeopardize trial results. Learn how standardized execution and equipment calibration protect data integrity and regulatory credibility.
-
![Elderly man with optomologist-GettyImages-840513864]( "Why Are Sponsors Prioritizing Ophthalmology Clinical Trials?")
Explore how demographic shifts and retinal innovation are transforming ophthalmology trials, and why operational precision is the key to protecting data integrity in this high-growth sector.
-
![GettyImages-1319939893-car-travel-road]( "Patient Centric Clinical Trials: Why Transportation Is A Timeline Risk")
Address transportation barriers to reduce protocol deviations and data gaps. Strategies that lower travel burden protect study timelines and improve visit adherence for better trial outcomes.
VIDEOS AND WEBINARS
CONTACT INFORMATION
20/20 Onsite
29 Garden Street
Everett, MA 02149
UNITED STATES
Phone: 617-812-9453
Contact: Jessica McKenzie, Vice President, Life Sciences
FEATURED PRODUCTS
FEATURED CASE STUDIES
-
![2020 in front of the mountains]( "FDA Fast-Tracked Clinical Trial")
Deconstruct the enrollment bottleneck in an ophthalmic gene therapy trial, discovering how point-of-need pre-screening cuts site activation delays and accelerates clinical development timelines.
-
![2020 uphill]( "Transforming Ophthalmic Assessments For A Mid-Trial Protocol Change")
Discover how a biopharmaceutical company integrated urgent mid-trial mandates across 65 sites, cutting standard onboarding timelines in half while preserving critical enrollment milestones.
-
![2020 Onsite Clinical Trial truck]( "GA Screening: Early Detection For Future Trial Recruitment")
Community-based screenings identify undiagnosed eye disease at high rates, creating a scalable, high-trust pathway for early intervention and improved clinical research recruitment.
-
![GettyImages-1391164235 eye disease]( "Enhancing Phase 1 Clinical Trials With Point-Of-Need Safety Assessments")
A Mobile Clinical Suite (MCS) proved to be the solution that Syneos Health needed to resolve their Phase 1 study trial challenges with comprehensive eye exams.
-
![Streamlining Phase 1 Trials with the Mobile Vision Pod]( "Streamlining Phase 1 Trials With The Mobile Vision Pod")
A contract research organization formed a partnership to address significant challenges during a Phase 1 clinical trial for a corneal disease treatment through the use of a Mobile Vision Pod.
-
![Expanding Diabetes-Related Eye Health Equity]( "Expanding Diabetes-Related Eye Health Equity")
20/20 Onsite, American Diabetes Association and Genentech collaborated on an event to provide immediate diagnostic services, including retinal imaging and visual acuity assessments, directly on-site.
-
![Expanding Access to Post-Market Safety]( "Expanding Access To Post-Market Safety Exams For Cystic Fibrosis Medication")
This study highlights the transformative impact of point-of-need care on patient access, focusing on pediatric cystic fibrosis (CF) patients requiring essential eye exams.
-
![Eye Care Delivered]( "Overcoming Unexpected Obstacles In A Phase 1 Study")
Discover how the implementation of mobile vision clinics (MVCs) was used to enhance efficiency in a Phase 1 clinical trial.
-
![IMG_6463]( "Advancing Rare Disease Clinical Trials With Point-Of-Need Eye Assessments")
During the COVID-19 pandemic, Applied Genetic Technologies Corporation (AGTC) faced significant hurdles in enrolling participants due to travel restrictions and site limitations.
-
![2020-onsite vehicle]( "Optimizing Chronic Cough Phase 3 Trials With Point-Of-Need Eye Assessments")
Collaboration was key for Company W to overcome challenges with an FDA-mandated ocular substudy, including limited resources for ocular assessments and logistical difficulties
